Coburn Josie, Bone Frederique, Hopkins Michael M, Stirling Andy, Mestre-Ferrandiz Jorge, Arapostathis Stathis, Llewelyn Martin J
Science Policy Research Unit, University of Sussex Business School, University of Sussex, Falmer, Brighton, United Kingdom.
Visiting Fellow, Office of Health Economics, London, United Kingdom.
Res Policy. 2021 May;50(4):104140. doi: 10.1016/j.respol.2020.104140.
This article provides prospective appraisal of key policy instruments intended to stimulate innovation to combat antimicrobial resistance (AMR). AMR refers to the ability of microbes to evolve resistance to those treatments designed to kill them, and is associated with the overuse or misuse of medicines such as antibiotics. AMR is an emerging global challenge with major implications for healthcare and society as a whole. Diagnostic tests for infectious diseases can guide decision making when prescribing medicines, so reducing inappropriate drug use. In the context of growing international interest in policies to stimulate innovation in AMR diagnostics, this study uses multicriteria mapping (MCM) to appraise a range of policy instruments in order to understand their potential performance while also highlighting the uncertainties that stakeholders hold about such interventions in complex contexts. A contribution of the article is the demonstration of a novel method to analyse and visualise MCM data in order to reveal stakeholder inclinations towards particular options while exploring interviewees' uncertainties about the effectiveness of each instrument's design or implementation. The article reports results from six European countries (Germany, Greece, Italy, the Netherlands, Spain and the UK). The findings reveal which policy instruments are deemed most likely to perform well, and why, across stakeholder groups and national settings, with areas of common ground and difference being identified. Importantly, the conclusions presented here differ from prominent policy discourse, with international implications for the design of mixes of policy instruments to combat AMR. Strategic and practical methodological implications also emerge for general appraisal of innovation policy instrument mixes.
本文对旨在促进创新以对抗抗菌药物耐药性(AMR)的关键政策工具进行了前瞻性评估。AMR是指微生物对旨在杀死它们的治疗方法产生耐药性的能力,与抗生素等药物的过度使用或滥用有关。AMR是一个新出现的全球性挑战,对整个医疗保健和社会都有重大影响。传染病诊断测试可以在开药时指导决策,从而减少不适当的药物使用。在国际上对促进AMR诊断创新的政策兴趣日益浓厚的背景下,本研究使用多标准映射(MCM)来评估一系列政策工具,以了解它们的潜在表现,同时突出利益相关者在复杂背景下对这类干预措施存在的不确定性。本文的一个贡献是展示了一种分析和可视化MCM数据的新方法,以便揭示利益相关者对特定选项的倾向,同时探究受访者对每种工具设计或实施效果的不确定性。本文报告了六个欧洲国家(德国、希腊、意大利、荷兰、西班牙和英国)的结果。研究结果揭示了在不同利益相关者群体和国家背景下,哪些政策工具被认为最有可能表现良好以及原因,同时确定了共同点和差异所在。重要的是,这里提出的结论与突出的政策论述不同,对对抗AMR的政策工具组合设计具有国际影响。对于创新政策工具组合的总体评估,也产生了战略和实际方法上的影响。